Date: 13-Aug-2019

Sandoz to appeal District Court of New Jersey ruling in biosimilar Erelzi US patent case

Sandoz, a Novartis division and a global leader in biosimilars, announced that the United States District Court of New Jersey ruled against Sandoz in patent litigation concerning the Sandoz biosimilar, Erelzi (etanercept-szzs) for reference medicine Enbrel (etanercept). The company will appeal the ruling to the US Court of Appeals for the Federal Circuit, and the parties have agreed to an expedited appeal.